Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016

  • ID: 3946484
  • Report
  • 442 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Boston Biomedical, Inc.
  • EpiZyme, Inc.
  • Fujifilm Corporation
  • Merck & Co., Inc.
  • MORE
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Relapsed Acute Myeloid Leukemia (Oncology) pipeline landscape.

Return of acute myeloid leukemia (AML) cells in the marrow and a decrease in normal blood cells after remission is called a relapsed acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment includes chemotherapy with the same or different drugs used previously during treatment.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 35, 35, 1, 3 and 1 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 2 molecules, respectively for Relapsed Acute Myeloid Leukemia.

Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Boston Biomedical, Inc.
  • EpiZyme, Inc.
  • Fujifilm Corporation
  • Merck & Co., Inc.
  • MORE
Introduction

Relapsed Acute Myeloid Leukemia Overview

Therapeutics Development

Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies

Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes

Relapsed Acute Myeloid Leukemia - Pipeline Products Glance

Relapsed Acute Myeloid Leukemia - Products under Development by Companies

Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes

Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development

Relapsed Acute Myeloid Leukemia - Therapeutics Assessment

Drug Profiles

Relapsed Acute Myeloid Leukemia - Dormant Projects

Relapsed Acute Myeloid Leukemia - Discontinued Products

Relapsed Acute Myeloid Leukemia - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016

Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by ADC Therapeutics Sarl, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Limited, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016

Relapsed Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Relapsed Acute Myeloid Leukemia - Dormant Projects, H2 2016

Relapsed Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016

Relapsed Acute Myeloid Leukemia - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016

Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
4SC AG
AbbVie Inc
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Aeglea BioTherapeutics, Inc.
Agios Pharmaceuticals, Inc.
Aileron Therapeutics, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
BioLineRx, Ltd.
BioSight Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cornerstone Pharmaceuticals, Inc.
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FLX Bio, Inc.
FORMA Therapeutics Inc
Fujifilm Corporation
GlaxoSmithKline Plc
GlycoMimetics, Inc.
Igenica Biotherapeutics, Inc.
Incyte Corporation
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
MacroGenics, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals Inc
NantKwest, Inc.
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sunesis Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Tolero Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll